Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
29 Items
Title  Creator  Group name  Publishing year 
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features Boissière-Michot et al. EquipeCTCS 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer Massa et al. EquipeCTCS 2024-12-01
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer Desroys du Roure et al. EquipePM 2024-01-30
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells Cherradi et al. EquipeMY 2023-04-11
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity Alcaraz et al. EquipeELC 2022-11-08
In situ hybridization for the assessment of urokinase plasminogen activator and plasminogen activator inhibitor type?1 in formalin?fixed paraffin?embedded breast cancer specimens Boissière-Michot et al. EquipeCTCS 2022-06
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer Boissière-Michot et al. EquipeELC 2022
Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer Bobrie et al. EquipeNB 2022-10-03
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers Jacot et al. EquipeELC 2021-12-01
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1) Assenat et al. EquipeMY 2021-02-01
MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis Kantar et al. EquipeAM 12/2021
CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers Boissière-Michot et al. EquipeCTCS 2021-05-12
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer Boissière-Michot et al. EquipeCTCS 2021-02-12
A Truncated NRIP1 Mutant Amplifies Microsatellite Instability of Colorectal Cancer by Regulating MSH2/MSH6 Expression, and Is a Prognostic Marker of Stage III Tumors Palassin et al. EquipeMY 2021
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment Alcaraz et al. EquipeCTCS 2021
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27) Samalin et al. EquipeMY May 15, 2020
Prognostic Value of CXCR2 in Breast Cancer Boissière-Michot et al. EquipeCTCS 2020-07-27
Identification of a regulatory V?1 gamma delta T cell subpopulation expressing CD73 in human breast cancer Chabab et al. EquipeCTCS 2020-06
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells Bourillon et al. EquipeAP Jan 17, 2020
Diversity of Tumor-Infiltrating, ?? T-Cell Abundance in Solid Cancers Chabab et al. EquipeNB Jun 24, 2020
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival Mansouri et al. EquipeCTCS 2020-05-15
BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer Jacot et al. EquipeMY 2020-03-30
The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex Kassouf et al. EquipePC Dec 07, 2019
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples Ho-Pun-Cheung et al. EquipeCTCS Dec 03, 2019
Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies Ashraf et al. EquipeAT Feb 04, 2019
12>>>
29 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés